Ke Ning, MD

Sarah Rockwell, PharmD, BCOP, and Ke Ning, MD, share their concluding remarks, reflecting on the current landscape and expressing their aspirations for addressing remaining unmet needs.

Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.

Medical professionals highlight the essential support provided by pharmacists in addressing operational challenges related to bispecific antibodies. Pharmacists can play an important role in the development of policies and procedures, monitoring and management of toxicities, and delivery of educational resources.

Sarah Rockwell, PharmD, BCOP, explores how community oncology practices can understand and meet the requirements of risk evaluation and mitigation strategy programs, and stresses the importance of developing and implementing standard operating procedures.

Key opinion leaders address the importance of coordination between academic hospital providers and community oncologists when transitioning from initiation of bispecific antibodies at a tertiary hospital to maintenance therapy in the community oncology setting.

The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.

Medical professionals share insights on treatment considerations and patient selection for bispecific antibody therapy and the process for referring patients to other institutions for care.